Key Points {#FPar1}
==========

Short-term, add-on treatment with brivaracetam oral solution was generally well tolerated by children with epilepsy aged \< 16 years.Plasma concentrations of brivaracetam and its metabolites increased proportionally with increasing dose.This trial also provides preliminary evidence that add-on brivaracetam treatment is effective in children with epilepsy.

Introduction {#Sec1}
============

Despite the availability of new antiepileptic drugs (AEDs), ≥ 25% of pediatric patients with epilepsy have inadequate seizure control on currently available AEDs, or experience significant adverse drug effects \[[@CR1]\]. Brivaracetam is a selective, high-affinity ligand for synaptic vesicle protein 2A that demonstrated positive phase III results as adjunctive treatment for focal (partial-onset) seizures in adults with epilepsy \[[@CR2]--[@CR4]\]. Brivaracetam is indicated as adjunctive therapy and monotherapy for the treatment of focal (partial-onset) seizures in patients aged ≥ 4 years (with injection indicated in those aged ≥ 16 years) in the USA and as adjunctive therapy for focal (partial-onset) seizures with or without secondary generalization in patients aged ≥ 4 years in the EU \[[@CR5], [@CR6]\] or in adults in other countries.

In healthy adults, brivaracetam is rapidly and completely absorbed, has a volume of distribution close to that of total body water, and has low plasma protein binding \[[@CR7]--[@CR9]\]. Brivaracetam is extensively biotransformed to three inactive metabolites by non-cytochrome P450 (CYP)-dependent hydrolysis of the acetamide group (acid metabolite \[BRV-AC\]; the primary pathway), CYP-dependent hydroxylation (hydroxy metabolite \[BRV-OH\]), and a combination pathway (hydroxy acid metabolite \[BRV-OHAC\]) \[[@CR8], [@CR10], [@CR11]\]. The oral solution and film-coated tablet formulations have demonstrated bioequivalence in healthy adults \[[@CR12]\].

The objectives of this trial were to assess the short-term safety and tolerability of adjunctive brivaracetam oral solution, to characterize the steady-state plasma concentrations of brivaracetam oral solution and its metabolites, and to obtain preliminary efficacy information in infants, children, and adolescents aged \< 16 years with epilepsy. An additional objective was to use the plasma concentration data to develop a population pharmacokinetic model to support dosing adaptations for children with epilepsy. This model has been published separately \[[@CR13]\].

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Patients aged ≥ 1 month to \< 16 years, with a body weight ≥ 3 kg, and with localized, generalized, or undetermined focal or generalized epileptic syndrome or other symptomatic generalized epilepsy, were included in the trial. The clinical diagnosis of epilepsy was supported using an electroencephalogram (EEG). Patients were taking at least one and no more than three concomitant AEDs (levetiracetam was prohibited), and had experienced one or more seizures during the 3 weeks before the trial. Patients were excluded if they had epilepsy secondary to a progressive cerebral disease, tumor, or any other progressive neurodegenerative disease; had status epilepticus in the month before screening or during the baseline period; had a history or presence of pseudoseizures; had febrile seizures only; or had previously received levetiracetam, unless discontinued at least 1 month before screening. Patients were also excluded if they had impaired hepatic function or had ever made a suicide attempt or had suicidal ideation during the previous 6 months as indicated by the Columbia-Suicide Severity Rating Scale completed at baseline. Pregnant or nursing females were not included.

To assess patients across a range of different age groups and with all types of epilepsy, patient enrollment was stratified by age category (infants and toddlers: 1 month to \< 2 years, at least 30 patients; children: 2 to \< 12 years, at least 30 patients; adolescents: 12 to \< 16 years, maximum 30 patients; a total of approximately 100 patients), and the number of patients with focal seizures was limited to 50% of the overall trial population.

Trial Design {#Sec4}
------------

This phase IIa, open-label, single-arm, fixed three-step dose-escalation trial (N01263; NCT00422422) was conducted at 29 centers in the USA, Mexico, Belgium, Czech Republic, Poland, and Spain between July 2011 and March 2013. The trial comprised a 1-week baseline period and a 3-week evaluation period, followed by either entry into a long-term trial (N01266; NCT01364597) or a ≤ 2-week downtitration period and a 2-week safety (post-treatment) period (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Trial design. For V3, V4, and V5 (pharmacokinetic visits), there was a visit window of +2 days. For V2, V6, and V7, there was a visit window of ± 2 days. ^a^Daily doses did not exceed 50, 100, and 200 mg/day at weeks 1, 2, and 3, respectively. ^b^For patients who did not enter the long-term trial or discontinued early. *bid* twice daily, *DL* dose level, *V* visit

Brivaracetam was administered as an oral solution (1 or 10 mg/mL). Dosages administered in pediatric patients were based on the linear pharmacokinetic profile and effective dose range (50--200 mg/day) observed in adults, and scaling by body weight and age using physiologically based pharmacokinetic simulations (UCB data on file). During the evaluation period, the dose of brivaracetam per kilogram body weight was escalated based on age: patients aged ≥ 8 years received approximately 0.8, 1.6, and 3.2 mg/kg/day in two divided daily doses at weeks 1, 2, and 3, respectively; patients aged \< 8 years received approximately 1.0, 2.0, and 4.0 mg/kg/day in two divided daily doses at weeks 1, 2, and 3, respectively. Maximum doses were 50, 100, and 200 mg/day at weeks 1, 2, and 3, respectively.

No additions or discontinuations of concomitant AEDs were permitted during the trial, and all concomitant AEDs were required to be at a stable dose \> 7 days before screening and throughout the trial. Benzodiazepines (if taken two or more times a week) and vagal nerve stimulators (if patients had a stable usage for \> 2 weeks before screening and throughout the trial) were considered concomitant AEDs. Felbamate was also prohibited unless patients had received it continuously for \> 18 months before screening.

The trial was conducted in accordance with the current version of the applicable regulatory and International Conference on Harmonization Good Clinical Practice requirements, the ethical principles as stated in the Declaration of Helsinki, and local laws of the countries involved. The trial protocol, amendments, and patient informed consent form were reviewed by a national, regional, or independent ethics committee or institutional review board. A written consent form was signed and dated by the parent(s) or legal guardian(s) of the patients, and, where required, a consent form or a specific assent form was also signed and dated by the patients.

Safety and Tolerability Assessments {#Sec5}
-----------------------------------

The safety and tolerability assessments performed throughout the trial were the occurrence of adverse events (AEs), laboratory tests, electrocardiograms (ECGs), body weight measurements, and monitoring of vital signs. AEs, coded using the Medical Dictionary for Regulatory Activities version 15.0, were summarized over the combined evaluation, downtitration, and safety periods. AEs were considered related to the trial drug if either the relationship to trial drug was specified as related by the investigator, or if the relationship to trial drug was not specified. Laboratory tests were conducted at baseline and following the high-dose treatment week (week 3). ECGs, monitoring of vital signs, and body weight measurements were carried out at baseline and the end of each trial week. Laboratory tests, ECGs, monitoring of vital signs, and body weight measurements were also carried out at a safety visit for patients not entering the long-term trial or 2 weeks after the last intake of trial drug for patients who discontinued early (see Fig. [1](#Fig1){ref-type="fig"} for trial design). Clinically significant abnormal values for laboratory values and vital signs were defined in the statistical analysis plan. The clinical significance of ECG results was determined by the investigator.

Plasma Concentration of Brivaracetam and Metabolites {#Sec6}
----------------------------------------------------

At least two blood samples were obtained for determination of plasma concentrations of brivaracetam and metabolites at the end of the low-, mid-, and high-dose treatment weeks (weeks 1, 2, and 3), or at the early discontinuation visit. Blood samples were taken in any one of three possible time brackets (early morning, late morning, or afternoon). For early morning, one sample was taken immediately before the morning dose of brivaracetam and one at 1--2 h post-dose; for late morning, two samples were taken 2--6 h after the morning dose of brivaracetam, with ≥ 2 h between sampling times; for the afternoon, two samples were taken 6--12 h after the morning dose of brivaracetam, with ≥ 2 h between sampling times. Plasma concentrations of brivaracetam and metabolites (BRV-AC, BRV-OH, and BRV-OHAC) were determined using liquid chromatography with tandem mass spectrometry detection \[[@CR13]\].

Efficacy Assessments {#Sec7}
--------------------

Seizures were recorded on daily record cards completed by the patient or parent/caregiver. Responder rate was calculated as the percentage of patients with ≥ 50% reduction in the number of seizure days (all seizure types) from the baseline period to the end of the evaluation period, standardized to a 28-day duration. Responder rate could therefore only be calculated in patients reporting at least one seizure during the baseline period. Exploratory efficacy variables were number of seizure days (all seizure types) over the evaluation period standardized to a 28-day duration, absolute and percent reduction from baseline in number of seizure days (all seizure types) per 28 days during the evaluation period, and seizure freedom rate during the evaluation period, defined as patients who completed the evaluation period with no missing diary days and no reported seizures.

Statistics {#Sec8}
----------

The safety set (SS) comprised all enrolled patients who took at least one dose of brivaracetam. Safety and tolerability outcomes are presented for the SS for all patients and the subgroup with a history of focal seizures with or without secondary generalization and no primary generalized seizures (all patients aged \< 16 years, \< 4 years, and 4 to \< 16 years). The pharmacokinetic per-protocol set (PK-PPS) comprised all patients with at least one measurable plasma sample (with recorded sampling time) on at least one visit with documented drug intake times. Plasma concentration results are shown for patients with a history of focal seizures (corresponding to the approved indication) split in three age bands (\< 4 years, 4 to \< 16 years, \< 16 years). The full analysis set (FAS) comprised all patients in the SS, with baseline and at least one completed post-baseline daily record card or EEG. Efficacy outcomes are presented descriptively for the FAS by seizure history and age group.

No imputation of missing values was performed for analysis parameters. Imputations for missing or partial values for dates for AEs and concomitant medications were applied to determine whether an event was to be considered treatment-emergent or concomitant. Only reported data were used in each analysis time interval.

Results {#Sec9}
=======

Patients {#Sec10}
--------

Overall, 100 patients entered the trial; 99 patients were included in the SS (one patient did not take any trial drug and was excluded), 96 were included in the PK-PPS, and 97 were included in the FAS. Of the 100 patients enrolled, 90 (90.0%) completed the trial and 10/100 (10.0%) discontinued (AEs: 6/100 \[6.0%\]; lack of efficacy: 1/100 \[1.0%\]; protocol violation: 1/100 \[1.0%\]; consent withdrawn: 2/100 \[2.0%\]).

Baseline demographic and epilepsy characteristics are presented in Table [1](#Tab1){ref-type="table"}. Overall, mean ± standard deviation age was 6.3 ± 4.8 years and body weight was 24.2 ± 16.2 kg. Of the overall population, approximately one-third (34/99 \[34.3%\]) were patients aged 4 to \< 16 years who had a history of focal seizures with or without secondary generalization and no primary generalized seizures. Among those, 22/34 (64.7%) experienced focal seizures during the 1-week prospective baseline period. The median duration of brivaracetam exposure during the evaluation period was 22 days (range 1--29) for both the total population and the subgroup with focal seizures aged 4 to \< 16 years. Overall, 81/99 (81.8%) patients were evaluated for 3--4 weeks.Table 1Demographic and baseline epilepsy characteristics (safety set)CharacteristicsPatients with focal seizures^a^Overall population^b^ (*n *= 99)Aged \< 4 years (*n *= 18)Aged 4 to \< 16 years (*n *= 34)Total (*n* = 52)Age (years)1.3 ± 0.7 (0.3--2.8)9.0 ± 4.0 (4.1--15.6)6.3 ± 4.9 (0.3--15.6)6.3 ± 4.8 (0.2--15.6)Sex, female6 (33.3)20 (58.8)26 (50.0)51 (51.5)Race White14 (77.8)26 (76.5)40 (76.9)79 (79.8) Black1 (5.6)3 (8.8)4 (7.7)4 (4.0) Other3 (16.7)5 (14.7)8 (15.4)16 (16.2)Weight (kg)10.0 ± 2.932.8 ± 14.624.9 ± 16.124.2 ± 16.2Age at epilepsy onset (years)0.4 ± 0.53.5 ± 3.82.4 ± 3.42.5 ± 3.3Time since diagnosis (years)0.8 ± 0.85.5 ± 4.03.9 ± 4.03.8 ± 3.7Epileptic syndrome^c^ Localization-related14 (77.8)33 (97.1)47 (90.4)51 (51.5) Generalized1 (5.6)01 (1.9)40 (40.4) Undetermined4 (22.2)04 (7.7)13 (13.1) Special syndromes01 (2.9)1 (1.9)4 (4.0)Seizure types experienced during baseline^c^ Focal15 (83.3)22 (64.7)37 (71.2)66 (66.7) Generalized00047 (47.5) Unclassified0006 (6.1)Baseline seizure days^d^17.6 ± 11.29.4 ± 10.812.2 ± 11.515.5 ± 11.2Number of prior AEDs 0--112 (66.7)10 (29.4)22 (42.3)37 (37.4) 2--45 (27.8)13 (38.2)18 (34.6)32 (32.3) ≥ 51 (5.6)11 (32.4)12 (23.1)30 (30.3)Number of concomitant AEDs 110 (55.6)10 (29.4)20 (38.5)32 (32.3) 25 (27.8)13 (38.2)18 (34.6)41 (41.4) ≥ 33 (16.7)11 (32.4)14 (26.9)26 (26.3)Concomitant AEDs^e^ Valproate6 (33.3)11 (32.4)17 (32.7)51 (51.5) Topiramate4 (22.2)12 (35.3)16 (30.8)27 (27.3) Lamotrigine09 (26.5)9 (17.3)17 (17.2) Clobazam3 (16.7)3 (8.8)6 (11.5)14 (14.1) Phenobarbital4 (22.2)2 (5.9)6 (11.5)14 (14.1) Oxcarbazepine3 (16.7)7 (20.6)10 (19.2)13 (13.1)Data are presented as *n* (%) or mean ± standard deviation (range) unless otherwise indicated*AED* antiepileptic drug^a^Patients with a history of focal seizures with or without secondary generalization and no primary generalized seizures at baseline^b^Patients with a history of any seizure type at baseline: focal, generalized, or unclassified^c^Patients could be included in more than one category^d^Number of seizure days, standardized to a 28-day duration; full analysis set^e^AEDs taken by ≥ 10% of patients overall

This article focuses on the subpopulation of children aged ≥ 4 years with focal seizures because, as detailed in the introduction, brivaracetam is currently indicated for the treatment of focal seizures in children aged ≥ 4 years with epilepsy, and health authorities (the European Medicines Agency \[EMA\] and the US FDA) have determined that efficacy can be extrapolated from adults to children aged ≥ 4 years \[[@CR14], [@CR15]\]. Data for the stratification age categories (1 month to \< 2 years, 2 to \< 12 years, 12 to \< 16 years) are shown in the Electronic Supplementary Material (Tables S1--4 Fig. S1).

Safety and Tolerability {#Sec11}
-----------------------

Throughout the trial, 66/99 (66.7%) patients/caregivers reported treatment-emergent adverse events (TEAEs); in 32/99 (32.3%) cases, TEAEs that the investigator considered related to trial drug were reported (Table [2](#Tab2){ref-type="table"}). Most TEAEs were considered mild or moderate in intensity. Six of 99 (6.1%) patients reported TEAEs leading to discontinuation, all of which were considered by the investigator to be related to trial drug. Two patients, both with a history of behavioral disturbances, discontinued brivaracetam due to aggression. One patient with a history of tuberous sclerosis discontinued brivaracetam due to abnormal behavior and eye movement disorder. The other TEAEs that led to discontinuation were decreased appetite (one patient), psychomotor hyperactivity/sleep disorder (one patient), and convulsion (one patient). No deaths were reported in the trial. During the evaluation period, the percentage of patients/caregivers reporting TEAEs during each dose-escalation step was 37.4%, 35.4%, and 27.4% for weeks 1, 2, and 3, respectively. Examination of individual TEAE data did not suggest a relationship with high plasma brivaracetam concentrations, although the numbers of patients were very limited.Table 2Summary of TEAEs and drug-related TEAEs reported during combined evaluation, downtitration, and safety (post-treatment) periods, and TEAEs during each week of the evaluation period (safety set)TEAEsPatients with focal seizures^a^Overall population^b^ (*n *= 99)Aged \< 4 years (*n *= 18)Aged 4 to \< 16 years (*n *= 34)Total (*n* = 52)At least one TEAE16 (88.9)23 (67.6)39 (75.0)66 (66.7)Severe TEAEs2 (11.1)02 (3.8)3 (3.0)Serious TEAEs4 (22.2)2 (5.9)6 (11.5)8 (8.1)Discontinuations due to TEAEs1 (5.6)5 (14.7)6 (11.5)6 (6.1)Deaths0000At least one TEAE in evaluation period Week 1 (low dose)9/18 (50.0)13/34 (38.2)22/52 (42.3)37/99 (37.4) Week 2 (mid dose)10/17 (58.8)13/32 (40.6)23/49 (46.9)34/96 (35.4) Week 3 (high dose)7/17 (41.2)9/31 (29.0)16/48 (33.3)26/95 (27.4)TEAEs (MedDRA version 15.0 preferred term) reported by ≥ 5% of all patients Convulsion3 (16.7)3 (8.8)6 (11.5)10 (10.1) Irritability3 (16.7)2 (5.9)5 (9.6)8 (8.1) Pyrexia4 (22.2)1 (2.9)5 (9.6)8 (8.1) Somnolence1 (5.6)3 (8.8)4 (7.7)8 (8.1) Decreased appetite2 (11.1)2 (5.9)4 (7.7)7 (7.1) Fatigue02 (5.9)2 (3.8)5 (5.1) Pharyngotonsillitis2 (11.1)1 (2.9)3 (5.8)5 (5.1)Drug-related^c^ TEAEs At least one drug-related TEAE6 (33.3)16 (47.1)22 (42.3)32 (32.3) Serious drug-related TEAEs01 (2.9)1 (1.9)1 (1.0)Drug-related^b^ TEAEs (MedDRA version 15.0 preferred term) reported by ≥ 3% of all patients Somnolence1 (5.6)3 (8.8)4 (7.7)7 (7.1) Decreased appetite2 (11.1)2 (5.9)4 (7.7)6 (6.1) Fatigue02 (5.9)2 (3.8)4 (4.0) Psychomotor hyperactivity03 (8.8)3 (5.8)3 (3.0) Aggression1 (5.6)2 (5.9)3 (5.8)3 (3.0) Irritability02 (5.9)2 (3.8)3 (3.0)Data are presented as n (%) or n/n (%)*MedDRA* Medical Dictionary for Regulatory Activities, *TEAE* treatment-emergent adverse event^a^Patients with a history of focal seizures with or without secondary generalization and no primary generalized seizures at baseline^b^Patients with a history of any seizure type at baseline: focal, generalized, or unclassified^c^According to the investigator or if relationship to treatment was not specified

Among patients with a history of focal seizures with or without secondary generalization and no primary generalized seizures aged 4 to \< 16 years, 23/34 (67.6%) patients/caregivers reported TEAEs (Table [2](#Tab2){ref-type="table"}). The most common TEAE in this subgroup was psychomotor hyperactivity (4/34 patients \[11.8%\]). Drug-related TEAEs were reported by 16/34 (47.1%) patients/caregivers, most commonly psychomotor hyperactivity and somnolence (each 3/34 \[8.8%\]). There were 2/34 (5.9%) patients with serious TEAEs (both convulsion), one of which was considered by the investigator to be drug-related. Examination of individual TEAE data did not suggest a relationship with the use of specific comedications, although the numbers of patients were very limited.

Two patients had clinically relevant ECG changes during the evaluation period, which were not associated with any AE; one patient had ventricular hypertrophy and left axis deviation that returned to normal after 3 weeks, and the other had sinus bradycardia with possible left ventricular hypertrophy, but presented with a normal ECG 1 week later. Neither patient discontinued brivaracetam because of these events. An additional patient reported ventricular extrasystoles as a TEAE, which was not considered to be related to the trial drug, so the brivaracetam dose was not altered. No clinically meaningful changes in laboratory tests, body weight, or vital signs were observed.

Plasma Concentration of Brivaracetam and Metabolites {#Sec12}
----------------------------------------------------

Trough plasma concentrations of brivaracetam and its metabolites increased proportionally with the brivaracetam dose, a finding that was consistent for each age group (Table [3](#Tab3){ref-type="table"}). At the end of each week in the evaluation period, geometric mean trough concentrations of brivaracetam and its metabolites were marginally higher in the group aged 4 to \< 16 years compared with the group aged \< 4 years. Broad interpatient variability was observed in the concentrations of brivaracetam and its metabolites. However, the differences for brivaracetam had *p* values of \> 0.05 (Wilcoxon rank-sum test, see Table [3](#Tab3){ref-type="table"}). Individual plasma concentration versus time profiles for brivaracetam at the low (day 7), mid (day 14), and high (day 21) dose levels is shown in Fig. S2 in the ESM. In addition, the relationship between predose plasma brivaracetam concentration and mg/kg dose in the overall population is illustrated in Fig. S3.Table 3Trough plasma concentrations of brivaracetam and its metabolites during the evaluation period for patients with focal seizures (pharmacokinetic-per-protocol set)Trough plasma concentration (µg/mL)^a^Patients with focal seizures^b^Aged \< 4 yearsAged 4 to \< 16 yearsTotalEnd of week 1 (low dose)*n *= 11*n *= 19*n *= 30Brivaracetam^c^0.201 (64.4)0.279 (81.0)0.247 (76.3)BRV-OH0.050 (78.8)0.061 (44.7)0.057 (58.0)BRV-AC0.008 (94.4)0.015 (77.3)0.012 (89.9)BRV-OHAC0.006 (43.1)0.008 (46.7)0.007 (48.4)End of week 2 (mid dose)*n* = 9*n* = 11*n* = 20Brivaracetam^d^0.348 (62.3)0.379 (58.3)0.365 (58.5)BRV-OH0.100 (63.1)0.123 (55.3)0.112 (58.3)BRV-AC0.016 (84.9)0.020 (66.2)0.018 (73.7)BRV-OHAC0.012 (34.9)0.014 (37.6)0.013 (36.1)End of week 3 (high dose)*n* = 7*n* = 11*n* = 18Brivaracetam^e^0.598 (60.6)0.761 (57.7)0.693 (58.5)BRV-OH0.200 (96.4)0.277 (56.0)0.244 (72.2)BRV-AC0.028 (77.9)0.048 (68.9)0.039 (77.6)BRV-OHAC0.019 (38.8)0.029 (43.6)0.024 (46.5)Data are presented as geometric mean (coefficient of variation %). All reported p-values can only be interpreted in an exploratory manner, i.e., are nominal*BRV*-*AC* acid metabolite of brivaracetam, *BRV*-*OH* hydroxy metabolite of brivaracetam, *BRV*-*OHAC* hydroxy acid metabolite of brivaracetam^a^Multiply by 4.713646 to convert concentrations from µg/mL to µmol/L. Metabolite concentrations are expressed in brivaracetam equivalents and use the same conversion factor^b^Patients with a history of focal seizures with or without secondary generalization and no primary generalized seizures at baseline^c^Wilcoxon rank-sum test for difference between groups aged \< 4 years and 4 to \< 16 years, *p* = 0.17^d^Wilcoxon rank-sum test for difference between groups aged \< 4 years and 4 to \< 16 years, *p* = 0.60^e^Wilcoxon rank-sum test for difference between groups aged \< 4 years and 4 to \< 16 years, *p* = 0.48

Exploratory Efficacy {#Sec13}
--------------------

Over the 3-week evaluation period, ≥ 50% responder rates (all seizure types) were 21.3% for all patients (*n* = 80) and 29.7% for patients with a history of focal seizures with or without secondary generalization and no primary generalized seizures (*n* = 37) (Fig. [2](#Fig2){ref-type="fig"}). Among patients with a history of focal seizures with or without secondary generalization and no primary generalized seizures, ≥ 50% responder rates were 20.0% for patients aged \< 4 years (*n* = 15) and 36.4% for those aged 4 to \< 16 years (*n* = 22).Fig. 2Responder rate based on a ≥ 50% reduction in seizure days from baseline to the end of the evaluation period, according to seizure diary data overall and by age and seizure category (full analysis set population). ^a^Patients with a history of any seizure type at baseline: focal, generalized, or unclassified. ^b^Patients with a history of focal seizures with or without secondary generalization and no primary generalized seizures at baseline. Note: Patients with a zero seizure count during the baseline period were excluded from the analysis as percent change from baseline could not be calculated (*n* = 17). *Numbers above bars* represent the number of patients who responded to treatment

In the overall trial population, the median number of seizure days (all seizure types; standardized to a 28-day duration) was 18.7 days during the baseline period and 16.0 days during the evaluation period, a median reduction of 4.8%.

The median reduction from baseline in number of seizure days (all seizure types) was 14.3% in patients with a history of focal seizures with or without secondary generalization and no primary generalized seizures, and 0.0% in patients with a history of primary generalized seizures (Table [4](#Tab4){ref-type="table"}).Table 4Number of seizure days (all seizure types) during baseline and evaluation periods and reduction from baseline in number of seizure days (full analysis set)Patients with focal seizures^a^Aged \< 4 yearsAged 4 to \< 16 yearsTotal*n *= 18*n *= 32*n *= 50Number of seizure days,^b^ median Baseline period21.74.38.9 Evaluation period17.83.46.3Absolute reduction from baseline in number of seizure days, median3.60.00.2Percent reduction from baseline in number of seizure days,^c^ median18.23.814.3Patients with primary generalized seizures^d^Aged \< 4 yearsAged 4 to \< 16 yearsTotal*n *= 18*n *= 27*n *= 45Number of seizure days,^b^ median Baseline period28.018.720.0 Evaluation period23.416.020.0Absolute reduction from baseline in number of seizure days, median0.00.00.0Percent reduction from baseline in number of seizure days,^e^ median0.02.40.0^a^Patients with a history of focal seizures with or without secondary generalization and no primary generalized seizures at baseline^b^Number of seizure days, standardized to a 28-day duration^c^Patients with a zero seizure count during the baseline period (*n* = 13) were excluded from the percent reduction analysis as percent change from baseline could not be calculated^d^Patients with a history of primary generalized seizures at baseline; patients could also have had focal seizures^e^Patients with a zero seizure count during the baseline period (*n* = 4) were excluded from the percent reduction analysis as percent change from baseline could not be calculated

The overall seizure freedom rate was 14/97 (14.4%). Complete seizure freedom was reported by 12/50 (24.0%) patients with a history of focal seizures with or without secondary generalization and no primary generalized seizures, comprising 4/18 (22.2%) patients aged \< 4 years and 8/32 (25.0%) aged 4 to \< 16 years.

Discussion {#Sec14}
==========

This is the first trial to evaluate brivaracetam in infants, children, and adolescents with epilepsy. The results of this phase IIa open-label trial showed that the treatment of pediatric patients aged 1 month to \< 16 years with adjunctive brivaracetam oral solution was generally well tolerated. Since TEAEs related to common childhood infectious diseases are frequently reported in pediatric populations (in this study, primary system organ class 'infections and infestations': 26/99 \[26.3%\]), drug-related TEAEs are often considered to be of greatest relevance in this population. The most commonly reported drug-related TEAEs were somnolence (7/99 \[7.1%\]) and decreased appetite (6/99 \[6.1%\]) in all patients, and psychomotor hyperactivity (3/34 \[8.8%\]) and somnolence (3/34 \[8.8%\]) in the subgroup aged 4 to \< 16 years with a history of focal seizures with or without secondary generalization and no primary generalized seizures. It should be noted that, because this trial was an open-label, 3-week, forced dose-escalation trial in infants and children with various epileptic syndromes (including focal seizures) and other symptomatic generalized epilepsies, the results cannot be directly compared with double-blind, placebo-controlled studies in adult patients with focal seizures only.

The current trial aimed to characterize the steady-state plasma concentrations of brivaracetam and its metabolites in pediatric patients. While the naïve pooled data analysis provided some evidence to suggest that trough plasma concentrations of brivaracetam may increase with age, non-linear mixed-effects modeling of the entire data set (i.e., also using non-trough plasma concentrations and demographic covariates) would be required to quantify the dose--concentration relationship among pediatric age groups. The related analysis was published elsewhere \[[@CR13]\]. Furthermore, external validation using independent studies with large patient numbers would be necessary to confirm these observations. In this trial, brivaracetam oral solution was administered over 3 weeks in two equal divided daily doses of approximately 0.8, 1.6, and 3.2 mg/kg/day for patients aged ≥ 8 years and 1.0, 2.0, and 4.0 mg/kg/day for patients aged \< 8 years. For each age group, trough brivaracetam and metabolite plasma concentrations increased proportionally with the weekly dose increases throughout the evaluation period, although high patient variability was observed and therefore no firm conclusions can be drawn. However, based on the data at the end of week 1, where patient numbers were larger, the mean concentrations of brivaracetam (and its metabolites) only increased minimally between age groups, suggesting that the dosages used were appropriate, despite potential differences in renal maturation and expression of hepatic isoenzymes and obvious body size differences in these distinct groups. As a side note, the apparent modest increase in brivaracetam plasma concentration is consistent with a decrease in weight-normalized clearance with increasing child age \[[@CR16]\]. Using this dosing regimen, no apparent increase in TEAEs was observed with increasing dose, which further supports the regimens used. The plasma concentrations of brivaracetam and demographic variables from this trial have been used to develop a population pharmacokinetic model of brivaracetam \[[@CR13]\] that was used to derive pediatric dosing adaptation rules; these are reported in another publication \[[@CR17]\].

The current trial provides preliminary evidence for the efficacy of adjunctive brivaracetam oral solution in pediatric patients. Among all patients who reported seizures during the baseline period (*n* = 80), the ≥ 50% responder rate was 21.3%, and 14.4% of all patients (*n* = 97) reported complete seizure freedom during the evaluation period. Although patient numbers were small, there was also preliminary evidence of efficacy in the subgroup of patients with a history of focal seizures aged 4 to \< 16 years, with a ≥ 50% responder rate of 36.4% (*n* = 22) and complete seizure freedom rate of 25.0% (*n* = 32). Extrapolation of efficacy data from adults to predict treatment response is now accepted by the FDA in children with focal seizures aged ≥ 4 years \[[@CR14]\], and similarly by the EMA for refractory focal seizures if the pediatric dose range is established \[[@CR15]\].

Findings from this trial should be interpreted with the caveat that patient numbers in the subgroups were small, which makes it difficult to interpret the data in patients aged \< 4 years. Similarly, tolerability and efficacy could not be inferred in any specific epileptic syndrome as patient numbers were not high enough. In addition, brivaracetam treatment was open label, there was no control group, and brivaracetam was only administered for 3 weeks. Furthermore, this trial had no requirement for seizures to be reported during the baseline period. Therefore, efficacy evaluations that measured the change in seizure frequency from baseline could not be performed in patients without any seizures during the baseline period (*n* = 17).

Conclusion {#Sec15}
==========

This trial in children aged \< 16 years with epilepsy showed that short-term, adjunctive treatment with brivaracetam oral solution was generally well tolerated. Steady-state trough plasma concentrations of brivaracetam and its metabolites increased proportionally with the brivaracetam dose. The trial also provides preliminary evidence that adjunctive brivaracetam treatment is effective in pediatric patients.
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